| 乳腺癌内分泌治疗进展 |
| |
| 引用本文： | 吴丽娜,吴荣. 乳腺癌内分泌治疗进展[J]. 国外医学(肿瘤学分册), 2007, 0(5) |
| |
| 作者姓名： | 吴丽娜 吴荣 |
| |
| 作者单位： | 中国医科大学附属第二医院肿瘤科，中国医科大学附属第二医院肿瘤科 |
| |
| 摘 要： | 乳腺癌的内分泌治疗是肿瘤综合治疗的重要组成部分之一。30多年来,三苯氧胺(TAM)已成为乳腺癌内分泌治疗的标准药物。第3代芳香化酶抑制剂的研制和开发,使乳腺癌内分泌治疗进入了一个崭新的时期。随着几个大型国际多中心、随机、双盲临床试验结果的不断公布,TAM在乳腺癌内分泌治疗中的金标准地位受到挑战。
|
| 关 键 词： | 乳腺肿瘤 治疗 芳香酶抑制剂 |
Development of endocrine therapy of breast cancer |
| |
| WU Li-na. Development of endocrine therapy of breast cancer[J]. Foreign Medical Sciences (Cancer Section), 2007, 0(5) |
| |
| Authors: | WU Li-na |
| |
| Affiliation: | WU Li-na Department of Oncology,the Second Affiliated Hospital of China Medical University,Shenyang 110021,China |
| |
| Abstract: | Endocrinotherapy is an important part of comprehensive treatment for breast cancer.In re- cent thirty years,Tamoxifen becomes the standard endotherapeutic drug for breast cancer.The appearance of the third generation aromatase inhibitors brings the endotherapy of breast cancer into a new era.As the publication of the results of several large,multi-center,randomized and double blind clinical trials,the gold standard station of tamoxifen is challenged. |
| |
| Keywords: | Breast neoplasms Therapy Aromatase inhibitors |
| 本文献已被 CNKI 等数据库收录！ |
|
